An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies
Cancer Diagnosis & Prognosis · 01.11.2023 · 3 (6) · 616-634
DOI: 10.21873/cdp.10264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.11.2023. Verfasst von Josiele DA Silva Prade und 11 weiteren Autor:innen. Beteiligte Einrichtung: Post-graduate Program in Health and Life Sciences, Franciscan University, Santa Maria, RS, Brazil. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Renal neoplasms are highlighted as one of the 10 most common types of cancer. Renal cell carcinoma (RCC) is the most common type of renal cancer, considered the seventh most common type of cancer in the Western world. The most frequently altered genes described as altered are VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, mTOR, TP53, TCEB1 (ELOC), SMARCA4, ARID1A, and PIK3CA. RCC therapies can be classified in three groups: monoclonal antibodies, tyrosine kinase inhibitors, and mTOR inhibitors. Besides, there are targeted agents to treat RCC. However, frequently patients present side effects and resistance. Even though many multidrug resistance mechanisms already have been reported to RCC, studies focused on revealing new biomarkers as well as more effective antitumor therapies with no or low side effects are very important. Some studies reported that natural products, such as honey, epigallocatechin-3-gallate (EGCG), curcumin, resveratrol, and englerin A showed antitumor activity against RCC. Moreover, nanoscience is another strategy to improve RCC treatment and reduce the side effects due to the improvement in pharmacokinetics and reduction of toxicities of chemotherapies. Taking this into account, we conducted a systemic review of recent research findings on RCC hallmarks, drug resistance, and adjuvant therapies. In conclusion, a range of studies reported that RCC is characterized by high incidence and increased mortality rates because of the development of resistance to standard therapies. Given the importance of improving RCC treatment and reducing adverse effects, nanoscience and natural products can be included in therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Post-graduate Program in Health and Life Sciences, Franciscan University, Santa Maria, RS, Brazil.
- Medicine Graduate Course, Franciscan University, Santa Maria, RS, Brazil.
- Biomedicine Graduate Course, Franciscan University, Santa Maria, RS, Brazil.
- Pharmacy Graduate Course, Franciscan University, Santa Maria, RS, Brazil.
- Laboratory of Nanostructured Magnetic Materials - LaMMaN, Franciscan University, Santa Maria, RS, Brazil.
- Graduate Program in Nanosciences, Franciscan University, Santa Maria, RS, Brazil.
Zitieren
APA
DA Silva Prade, J., DE Souza, R. S., DA Silva D'Αvila, C. M., DA Silva, T. C., Livinalli, I. C., Bertoncelli, A. C. Z., Saccol, F. K., DE Oliveira Mendes, T., Wenning, L. G., DA Rosa Salles, T., Rhoden, C. R. B., & Cadona, F. C. (2023). An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies. Cancer Diagnosis & Prognosis, 3(6), 616-634. https://doi.org/10.21873/cdp.10264
Vancouver
DA Silva Prade J, DE Souza RS, DA Silva D'Αvila CM, DA Silva TC, Livinalli IC, Bertoncelli ACZ, et al. An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies. Cancer Diagnosis & Prognosis. 2023;3(6):616-634. doi:10.21873/cdp.10264
BibTeX
@article{DASilvaPrade2023,
author = {DA Silva Prade, Josiele and DE Souza, Ruan Soares and DA Silva D'Αvila, Camila Medianeira and DA Silva, Thayline Correia and Livinalli, Isadora Cassel and Bertoncelli, Ana Clara Zanini and Saccol, Fernanda Krapf and DE Oliveira Mendes, Tallys and Wenning, Larissa Gindri and DA Rosa Salles, Theodoro and Rhoden, Cristiano Rodrigo Bohn and Cadona, Francine Carla},
title = {An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies},
journal = {Cancer Diagnosis & Prognosis},
year = {2023},
volume = {3},
number = {6},
pages = {616--634},
doi = {10.21873/cdp.10264}
}
EUVIMED